@entity295 due to coagulase-negative XXXX in a community hospital.

@entity1 @entity3256 @entity295 @entity2176 @entity5938 @entity3405 @entity2886 @entity580 @entity72282
The experience with @entity295 due to coagulase-negative @entity5938 at a 623-bed primary care hospital between 1980 and 1984 was reviewed. A total of 38 episodes in 37 @entity1 were documented; data were available on 37 episodes in 36 @entity1 . The organism accounted for 3.8% of all cases of @entity295 and 6.7% of cases of @entity295 and was associated with 0.03% of all admissions. The incidence remained stable over the 5 years. The rate of survival 28 days after the episode was 78%. Most of the episodes (31) originated from infected vascular access sites. Of the 37 isolates 15 (41%), all @entity5938 , were slime producing. @entity5938 accounted for 33 of the isolates; of the 33, 5 were @entity3256 -resistant and slime producing. Various in-vitro susceptibility testing methods and testing for @entity72282 production yielded conflicting results. @entity3256 resistance, slime production and speciation as @entity5938 were not confirmed as virulence markers. Five @entity1 with @entity3256 -resistant organisms were treated with @entity2886 , and all recovered. These findings as well as examination of the literature do not support the recommendations that laboratories report such isolates as resistant to all @entity3405 agents and that @entity2176 be given in all such infections. The different case mix in community hospitals as compared with university centres results in different patterns of @entity580 . Since the community hospital @entity1 population is much larger, more information on the patterns of infections in these centres is needed.
